Asian Stocks Slip Ahead of Fed Decision as China Deflation Concerns Deepen 
Gulf Sovereign Funds Unite in Paramount–Skydance Bid for Warner Bros Discovery 
Oil Prices Edge Higher as U.S. Seizes Sanctioned Venezuelan Tanker 
Nvidia Develops New Location-Verification Technology for AI Chips 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Brazil Holds Selic Rate at 15% as Inflation Expectations Stay Elevated 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
Gold Prices Dip as Markets Absorb Dovish Fed Outlook; Silver Eases After Record High 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Asian Stocks Slip as Oracle Earnings Miss Sparks AI Profitability Concerns 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
BOJ Expected to Deliver December Rate Hike as Economists See Borrowing Costs Rising Through 2025 
Wall Street Futures Slip as Oracle Earnings Miss Reignites AI Spending Concerns 
Merck KGaA has signed partnership deals with BenevolentAI and Exscientia for its AI-driven drug discovery push. The German science and technology company is collaborating with these AI drug discovery firms to strengthen its own capabilities in designing and creating new drugs using artificial intelligence.
As per Fierce BioTech, Merck KGaA is betting on an AI-enabled future for drug discovery the new deals with BenevolentAI and Exscientia are part of its strategy to meet its own goals. Based on the reports, the contracts are worth over $30 million upfront and up to $1 billion in possible milestone arrangements.
In any case, with its collaborations with two leading AI drug discovery groups, Merck just bolstered its chances of yielding successful results for its targeted development and production of new drugs on three leading categories in the medical fields, which are immunology, neuroinflammation, cancer, and neurology
Merck’s global head of R&D also said that the incorporation of science, AI, and data could allow them to find and produce “previously unimaginable medical breakthroughs.” Although the AI-enabled drug discovery method is still in the early stages, the company is positive that it will achieve its goals while also becoming a pioneer in this field.
“With the convergence of science, data, and AI, we're determined to fast-track the development of new and truly innovative candidates, forging a path to previously unimaginable medical breakthroughs,” Merck’s global head of research and development and chief medical officer for the healthcare business unit, Danny Bar-Zohar, said in a press release.
He added, “The partnerships with industry-leading AI technology firms BenevolentAI and Exscientia will complement our internal research capabilities and expertise, aligning with our broader strategy to enhance R&D productivity and the output of our pipeline in a sustainable manner.”
Photo by: Merck Group Media Gallery
